Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod
The drug, larotrectinib, will be sold under the brand name Vitrakvi in partnership with Bayer AG.
The mutation, known as TRK fusion, occurs in no more than 3,000 Americans each year, or less than 1 percent of patients with solid tumor cancers, according to Bayer. (Reporting By Deena Beasley Editing by Bill Berkrot)
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)